Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

OW 2026 15 November 2026

REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults With Overweight or Obesity

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress poster
Amylin
CagriSema
PHASE 3 (RCT)